Telormedix Secures Further Funding
10. Januar 2012
On 10 January 2012 Telormedix SA (Bioggio, Switzerland), a clinical stage biopharmaceutical company focused on target immunity in the treatment of cancer and other diseases, announced that it has raised 7.5 Million CHF from existing investors Aravis Venture (Basel, Switzerland) and Proquest Investments (Princeton – San Diego, USA).
The money raised in this financing round will be used to further advance Telormedix’s product candidates through preclinical and clinical trials.
A team of Froriep Renggli, lead by Marco A. Rizzi, acted as legal advisor in the funding.